Future vision for the quality assurance of oncology clinical trials

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  FitzGerald, Thomas J ^a,b   Bishop Jodoin, Maryann ^a   Bosch, Walter R ^c   Curran, Walter J ^d   Followill, David S ^e   Galvin, James M ^f,g   Hanusik, Richard ^a   King, Steven R ^h   Knopp, Michael V ⁱ   Laurie, Fran ^a   O'Meara, Elizabeth ^g   Michalski, Jeff M ^c   Saltz, Joel H ^d   Schnall, Mitchell D ^j   Schwartz, Lawrence ^k   Ulin, Kenneth ^a,b   Xiao, Ying ^f,g   Urie, Marcia ^a  

^a Quality Assurance Review Center   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g RADIATION THERAPY ONCOLOGY GROUP   (United States)

^h AMERICAN COLLEGE OF RADIOLOGY   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^k Howard Hughes Medical Institute   (United States)

more..

Author keywords

Clinical Trials Cooperative Group Program; National cancer institute; Oncology clinical trials; Quality assurance; Radiation oncology

Indexed keywords

ACCREDITATION; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; INFORMATION PROCESSING; INTENSITY MODULATED RADIATION THERAPY; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OVERALL SURVIVAL; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; REVIEW; STUDY DESIGN;

EID: 84888286988     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00031     Document Type: Review

References (20)

1. Abrams, R. A., Winter, K. A., Regine, W. F., Safran, H., Hoffman, J. P., Lustig, R., et al. (2012). Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 82, 809-816.
2. Chang, D. T., Feigenberg, S. J., Indelicato, D. J., Morris, C. G., Lightsey, J., Grobmyer, S. R., et al. (2007). Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection. Int. J. Radiat. Oncol. Biol. Phys. 67, 1043-1051.
3. Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439.
4. D'Angio, G. J. (1980). Introduction: total body irradiation conference. Int. J. Radiat. Oncol. Biol. Phys. 6, 744.
5. Dharmarajan, K. V., Friedman, D. L., FitzGerald, T., McCarten, K. M., Constine, L. S., Kessel, S. K., et al. (2012a). Radiation therapy quality assurance on AHOD0031: a report from the Quality Assurance Review Center (QARC) and the Children's Oncology Group. American Society for Radiation Oncology 54th Annual Meeting, Boston, MA. Int. J. Radiat. Oncol. Biol. Phys. 84, S162.
6. Dharmarajan, K. V., Friedman, D. L., Schwartz, C. L., Chen, L., FitzGerald, T., McCarten, K. M., et al. (2012b). Patterns of relapse from a phase III study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. American Society for Radiation Oncology 54th Annual Meeting, Boston, MA. Int. J. Radiat. Oncol. Biol. Phys. 84, S5-S6.
7. FitzGerald, T. J., Urie, M., Ulin, K., Laurie, F., Yorty, J., Hanusik, R., et al. (2008). Processes for quality improvements in radiation oncology clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 71, S76-S79.
8. Galvin, J. M., D'Angio, G. J., and Walsh, G. (1980). Use of tissue compensators to improve dose uniformity for total body irradiation. Int. J. Radiat. Oncol. Biol. Phys. 6, 767-771.
9. Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., et al. (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976-983.
10. Institute of Medicine of the National Academies. (2010). A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Available at: http://iom.edu/Reports/2010/A-National-Cancer-Clinical-Trials-System-for-the-21st-Century-Reinvigorating-the-NCI-Cooperative.aspx
11. Kachnic, L. A., Winter, K., Wasserman, T., Kelsen, D., Ginsberg, R., Pisansky, T. M., et al. (2011). Longitudinal quality-of-life analysis of RTOG 94-05 (Int 0123): a phase III trial of definitive chemoradiotherapy for esophageal cancer. Gastrointest. Cancer Res. 4, 45-52.
12. Kim, T. H., Khan, F. M., and Galvin, J. M. (1980). A report of the work party: comparison of total body irradiation techniques for bone marrow transplantation. Int. J. Radiat. Oncol. Biol. Phys. 6, 779-784.
13. Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., et al. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 337, 949-955.
14. Peters, L. J., O'Sullivan, B., Giralt, J., Fitzgerald, T. J., Trotti, A., Bernier, J., et al. (2010). Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 28, 2996-3001.
15. Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., et al. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337, 956-962.
16. Sartor, C. I., Peterson, B. L., Woolf, S., Fitzgerald, T. J., Laurie, F., Turrisi, A. J., et al. (2005). Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J. Clin. Oncol. 23, 30-40.
17. Schwartz, C. L., Constine, L. S., Villaluna, D., London, W. B., Hutchison, R. E., Sposto, R., et al. (2009). A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425. Blood 114, 2051-2059.
18. Tebbi, C. K., Mendenhall, N., London, W. B., Williams, J. L., de Alarcon, P. A., Chauvenet, A. R., et al. (2006). Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr. Blood Cancer 46, 198-202.
19. Weiner, M. A., Leventhal, B., Brecher, M. L., Marcus, R. B., Cantor, A., Gieser, P. W., et al. (1997). Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J. Clin. Oncol. 15, 2769-2779.
20. Wolden, S., Constine, L., Schwartz, C. L., Friedman, D., McCarten, K., Laurie, F., et al. (2009). Real Time Diagnostic Imaging Central Review and Radiotherapy Interventional Review in Multicenter Cancer Trials. Montreal: PROS Congress.